M. Nakatogawa

Rationale and design of a multicentre, 12-week, randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated trial to investigate the efficacy and safety of elobixibat for chronic constipation

A. Nakajima, M. Taguri, K. Ariyoshi, 2022, BMJ Open.

Autophagy and lipid homeostasis

H. Nakatogawa, M. Nakatogawa, 2018 .

Exploratory, multicenter, open-label study to evaluate the effects of linaclotide in patients with chronic constipation with an insufficient response to magnesium oxide: A study protocol

T. Higurashi, Takaomi Kessoku, T. Takatsu, 2022, Contemporary clinical trials communications.

Rationale and design of a multicenter, single-group, open-label trial aiming at investigating the effectiveness of elobixibat for loss of defecation desire in patients with chronic constipation

A. Nakajima, M. Taguri, K. Ariyoshi, 2022, Contemporary clinical trials communications.

Editorial :Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). DOI: 10.1080/15548627.2015.1100356;WOS:000373595400001; 2-s2.0-85013763791&;PMID: 26799652

Lee, Duchen, Izzo, 2016 .